The tyrosine kinase inhibitor taletrectinib has been approved for use in patients with ROS1-positive non-small cell lung cancer. The FDA has granted approval to the tyrosine kinase inhibitor (TKI) ...

T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06. Fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) ...

Education before subcutaneous daratumumab administration can both reassure patients and reduce the occurrence of adverse ...

Oncology nurses and APPs can help reduce discrimination faced by patients with cancer who are members of the LGBTQIA+ ...

Adding olanzapine (Zyprexa) to a standard antiemetic regimen displayed safety and efficacy in preventing radiation-induced nausea and vomiting (RINV) for patients receiving abdominal/pelvic ...

Retifanlimab-dlwr (Zynyz) was granted approval from the FDA for treatment of locally recurrent or metastatic squamous cell ...

Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to ...

By monitoring patients’ CBC and other symptoms, nurses and advanced practice providers can spot early indicators of Parkinsonism risk, per Yi Lin, MD, PhD.

A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, ...

Panelists discuss strategies for medication adherence and patient education, emphasizing the importance of proactive communication and support from the entire health care team.

Panelists discuss how real-world data from the San Antonio Breast Cancer Symposium demonstrated that elacestrant's ...